Combined effects of vasoactive intestinal peptide and dopamine on adenylate cyclase in prolactin-secreting cells.

Oliva D, Vallar L, Giannattasio G, Spada A, Nicosia S

Peptides1 Nov 1984Cited by 5 (Europe PMC)

PMID6531270DOI10.1016/0196-9781(84)90172-4PepBankPUB-06531270

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
VIP stimulated adenylate cyclase activity of male and female rat anterior pituitaries.
In plain wordsIn rat pituitary tissue, VIP stimulated adenylate cyclase activity.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseAdenylate cyclase activity in rat anterior pituitary
Study
ratn: not reported in source
male and female rat anterior pituitaries
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
VIP stimulates adenylate cyclase activity of male and female rat anterior pituitaries
Report a problemFND-0653127001
02LabEx vivo tissueActivity measurement
VIP stimulated adenylate cyclase activity of human prolactinomas.
In plain wordsIn human prolactinoma tissue, VIP stimulated adenylate cyclase activity.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseAdenylate cyclase activity in human prolactinomas
Study
humann: not reported in source
human prolactinoma tissue
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
VIP stimulates adenylate cyclase activity of male and female rat anterior pituitaries and human prolactinomas
Report a problemFND-0653127002

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
In male rats, a dopamine-inhibited adenylate cyclase could be detected when the enzyme activity was increased by VIP; VIP was used as a tool to show dopamine inhibition.
In plain wordsIn male rat pituitary tissue, dopamine's inhibition of adenylate cyclase showed up once VIP had raised the enzyme activity.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseDopamine-inhibited cyclase in male rats when raised by VIP
Study
ratn: not reported in source
male rat anterior pituitary
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
A dopamine inhibited cyclase can be detected also in male rats provided the enzyme activity is increased by VIP.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0653127003
04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
In female rat pituitaries and human prolactinomas, the dose-response curves for dopamine with or without VIP, and for VIP with or without dopamine, were parallel, so VIP and dopamine acted independently.
In plain wordsIn female rat pituitary tissue and human prolactinoma tissue, VIP and dopamine acted independently of each other.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeInteraction of VIP and dopamine in female rat pituitaries and human prolactinomas
Study
rat, humann: not reported in source
female rat pituitaries and human prolactinomas
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
In fact, in female rat pituitaries and in human prolactinomas, the curves for dopamine +/- VIP and for VIP +/- dopamine were parallel, indicating that the two agents exherted their effects independently from one another.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0653127004
05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
In male rat pituitaries, VIP greatly amplified the inhibitory effect of dopamine on adenylate cyclase, with non-parallel dose-response curves.
In plain wordsIn male rat pituitary tissue, VIP made dopamine's blocking effect on adenylate cyclase much stronger.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseInteraction of VIP and dopamine in male rat pituitaries
Study
ratn: not reported in source
male rat anterior pituitary
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
On the contrary, in male rat pituitaries, the curves were definitively non parallel, that is, the inhibitory effect of dopamine was greatly amplified by VIP.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0653127005
06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
In no case was the apparent affinity (EC50) of VIP or dopamine modified by the presence of the other agent.
In plain wordsIn rat and human pituitary tissue, neither VIP nor dopamine changed the other's apparent affinity.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeApparent affinity (EC50) of VIP and dopamine in the presence of the other agent
Study
rat, humann: not reported in source
rat pituitaries and human prolactinomas
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
In no case was the apparent affinity (EC50) of one agent modified by the presence of the other.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0653127006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.